Pharma major Lupin announced the launch of Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg is the generic equivalent of SPECGX LLC’s Anafranil® Capsules, 25 mg, 50 mg, and 75 mg. It is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).
Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg had annual sales of $96.2 million in the US (IQVIA MAT December 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.